Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — Investor Presentation (January 2026)
24 slides from Sudarshan Pharma Industries's investor presentation, Jan 31, 2026
Slide 1: BSE filing cover letter: Investor Presentation disclosure
OUDARSHAT PHAR]IA IXDUOTRIES tID Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S,V, Road, Borivali (West), Mumbai - 400092. . E-mail : compliance@sudarshanpharma.com, Website : wwwsudarshanpharma.com Board Line i +91-22-42221111 I 43331111142221116 (100 line) CIN: 1514961VH2008P1C1849
Slide 2: Sudarshan Pharma Industries Limited Investor Presentation
Sudarshan Pharma Industries Limited “Innovating Chemistry, Empowering Health” INVESTOR PRESENTATION E-mail : Compliance@sudarshanpharma.com Website : www.sudarshanpharma.com Contact No : CS Nirav Shah : 7700966328
Slide 3: Milestones 2008-2018
Milestones 2008- 2011- 2013- 2015- 2017- 2010 2012 2014 2016 2018 • 2008 - Expanded • Generic • Established our • Over 5,000 medical • Manufacturing of market reach by formulations for footprints in practitioners Nutraceuticals. importing high- institution supply, Gujarat, West associated with quali
Slide 4: Milestones 2019-2026
Milestones 2019- 2021- 2023- 2024- 2025- 2020 2022 2024 2025 2026 • *Nutraceuticals • IVD-Section Got • New unit • Acquired subsidiary • Proposed fund- Plant project cost 50Cr. Govt. Order. development in in Singapore raising of FCCB of is Rs. 2.5 Cr. And • Successfully Palghar. • Incorporated USD 3
Slide 5: Existing Business Layout
Existing Business Layout Business Layout The company is focusing on increasing manufacturing capabilities and has started Vertical Integration for expansion in the following segments: Branded Generics Finished Formulation and F&O Research & API Manufacturing Development and Import Intermediates for
Slide 6: Subsidiaries
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LIMITED Wholly Owned Subsidiaries 51% Ownership Ratna Lifescience Private Limited Life Science Chemical Private Limited Ishwari Healthcare Private Limited Products: Products: Products: •Gemcitabine Hydrochloride • Tannin extracts • Polyglycolic Acid Sutures •
Slide 7: Subsidiaries
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Wholly Owned Subsidiaries 70% Ownership Sudarshan Pharma Sudarshan Pharma Lifescience Private Cibachem General Trading Sudarshan Maven Industries Private Limited, LLC, Dubai Pharma Private Limited Singapore Limited Products: The Company is in the Product
Slide 8: Sudarshan Pharma – Srigen New Manufacturing Unit
SUDARSHAN PHARMA – SRIGEN NEW MANUFACTURING UNIT Hyderabad Unit Hyderabad Unit is bulk drug & intermediate manufacturing unit. It has developed about 50 potential API Key starting materials and also having an outstanding commercial technology. Few key starting materials hold Patent rights and those
Slide 9: Key Value Proposition
Key value Proposition Why Invest in Sudarshan Pharma Industries Limited The Company delivers trusted pharmaceutical solutions through a strong focus on quality, compliance and long-term partnerships. With a robust portfolio of Specialty Chemicals, Advanced Intermediates, Active Pharmaceutical Ingred
Slide 10: Market Pain Point & Opportunity We Address
Market Pain Point & Opportunity We Address The global pharmaceutical supply chain faces a critical challenge due to high dependency on China for raw material of specialty chemicals, intermediates and excipients. This dependency exposes manufacturers to price volatility, inconsistent supply, geopolit
Slide 11: Our Solution – The Sudarshan Advantage
Our Solution – The Sudarshan Advantage Sudarshan Pharma Industries Limited | Investor Presentation
Slide 12: Focused Market
FOCUSED MARKET New Export Avenues New Clintele USA Canada China UK Poland Netherlands UAE Jordan Lebanon Oman Qatar Major African Markets Congo Nigeria Cameroon Morocco Uganda Australia Singapore Nepal Taiwan Saudi Rwanda Mali Kenya Ghana Somalia Bangladesh Srilanka Pakistan Algeria Mauritius Sudars
Slide 13: Lead Management
Lead Management Mr. Hemal V. Mehta |Chairman & Managing Director Hemal Mehta, Founder-Promoter and Chairman & Managing Director of Sudarshan Pharma Industries Ltd., brings 26 years of extensive experience in the pharmaceutical and chemical manufacturing industry. He is recognized for his expertise i
Slide 14: Board of Directors
Board of Directors Vijay Ojha| Independent Director Jaya Singhania| Independent Director Registered as an Independent Director with the Dr. Vijay Ojha is a result oriented Biotech Professional databank of IICA. She has authored numerous with General Management knowledge having about write-ups on cor
Slide 15: Senior Key Personnel
Senior Key Personnel 1. Mr. Raju Sanghvi Senior Accountant 7. Mrs. Namrata Mehta Vice President (Sales) 2. Mr. Santosh Thakur Import Manger 8. Mr. Bhavesh Kanakia Vice President - Purchase 3. Mr. Shrinivas Patil Sales Manager 9. Mr. Amit Yadav Finance Manager 4. Mrs. Shrishti Mayekar Sales Head 10.
Slide 16: Senior Key Personnel
Senior Key Personnel 13. Mr. Milan Shah Purchase Manager 19. Mr. Mayank Vyas President (Business Development Manager) 14. Mr. Nirav Shah CS & Compliance Officer 20. Mr. Vishal Bhosale Production Head (Jejuri) 15. Mr. Vasantrai Mehta President (Admin) 21. Mr. Kuldeep Devgude QC (Jejuri) Production he
Slide 17: Senior Consultants
Senior Consultants Dr. Vishwas Joshi Dr. S Venkat Rao Dr. Lanka Rao Mr. Dhrumit Patel Dr. Rajesh Patil Dr. Purshotam Madupu Sudarshan Pharma Industries Limited | Investor Presentation
Slide 18: Our Esteemed Clientele
OURESTEEMED CLIENTELE Sudarshan Pharma Industries Limited | Investor Presentation
Slide 19: Consolidated Profit & Loss Account (Rs. in Crores)
Consolidated Profit &Loss Account (Rs. in Crores) . PARTICULARS QUARTER ANNUAL 31.12.2025 30.09.2025 30.06.2025 31.03.2025 INCOME Revenue from Operations 168.01 168.87 145.26 505.04 Other Income 1.52 1.86 1.21 2.66 Total Income (I) 169.52 170.73 146.47 507.69 EXPENSES Cost of Materials Consumed 13.2
Slide 20: Financial Metrics: Focus on Margin Optimization and Profit Growth
Financial Metrics: Focus on Margin Optimizationand Profit Growth Revenue from Operations Operating EBITDA & EBITDA Margin (%) PAT & PATMargin (%) INR in Crs 7.3% 6.2% 8.4% 4.9% 7.9% 2.6% 2.8% 3.2% 2.5% 3.6% +9.0% +75.0% +39.3% 505.0 463.5 39.9 16.0 +62.0% +51.9% +19.6% 11.5 10.0 314.1 23.4 22.8 227.
Slide 21: Financial Performance
FINANCIAL PERFORMANCE : Revenue from Operations (Rs Cr) EBITDA (Rs Cr) PAT(Rs Cr) 3.1% 3.2% 4.9% 7.9% 1.5% 1.5% 2.5% 3.2% +12% 463.5 505.0 39.9 +45% 16.0 461.3 +54% 357.1 11.5 22.8 14.7 7.0 10.9 5.2 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 R0CE (%) ROE (%) Debt to Equity (x) 39.9
Slide 22: Historical Consolidated Profit & Loss Statement
HistoricalConsolidatedProfit & Loss Statement (Rs. In Crores) .PARTICULARS 31.03.2025 31.03.2024 31.03.2023 INCOME Revenue from Operations 505.05 463.54 461.33 Other Income 2.52 2.61 1.12 Total Income (I) 507.57 466.15 462.45 EXPENSES Cost of Materials Consumed 8.93 6.31 0.32 Purchase of Stock-in-Tr
Slide 23: Historical Consolidated Balance Sheet
HistoricalConsolidatedBalance Sheet (Rs. in Crores) PARTICULARS 31.03.2025 31.03.2024 31.03.2023 I. EQUITY AND LIABILITIES (1) Shareholder's Funds Share Capital 24.07 24.07 24.07 Reserves and Surplus 103.52 87.64 76.91 (2) Non-Current Liabilities Long-Term Borrowings 10.46 10.49 12.79 Other Long Ter
Slide 24: Thank you
Thank you rr
Sudarshan Pharma Industries — Investor Presentation (January 2026) on 6ix